Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is a antimetabolite (folate antagonist) presented as an injectable solution for intraarterial, intramuscular, intravenous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer in appropriate patient populations.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, with established logistics for regulated medicines and compliance with local regulations.

Methotrexate is an antimetabolite used in several autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: limits skin cell proliferation and improves plaque appearance. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: induces tumor cell death and contributes to disease control. - Breast cancer: used as part of combination regimens to inhibit tumor growth.

Methotrexate may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral ulcers or mucositis. - Mild elevation of liver enzymes. - Decreased white blood cell count. - Alopecia (hair thinning).

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Secondary malignancies. - Severe infections requiring hospitalization.

Methotrexate therapy requires careful monitoring and patient education. - Baseline monitoring: obtain complete blood count, liver and renal function before initiating therapy. - Pregnancy risk: avoid use in pregnancy unless benefits clearly outweigh risks; advise effective contraception. - Infection risk: monitor for signs of infection and avoid live vaccines during treatment. - Renal impairment: adjust dose or consider alternative therapy in severe renal dysfunction. - Drug interactions: review concomitant medications for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins (e.g., ampicillin): reduce renal clearance and raise serum levels. - Proton pump inhibitors (omeprazole, esomeprazole): may elevate methotrexate concentrations. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Sulfonamides: may increase methotrexate toxicity. - Azathioprine: additive bone‑marrow suppression. - Trimethoprim‑sulfamethoxazole: similar risk of enhanced toxicity.